Log in to save to my catalogue

Long-term neurocognitive functioning of children treated with propranolol or atenolol for infantile...

Long-term neurocognitive functioning of children treated with propranolol or atenolol for infantile...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9899165

Long-term neurocognitive functioning of children treated with propranolol or atenolol for infantile hemangioma

About this item

Full title

Long-term neurocognitive functioning of children treated with propranolol or atenolol for infantile hemangioma

Publisher

Berlin/Heidelberg: Springer Berlin Heidelberg

Journal title

European journal of pediatrics, 2023-02, Vol.182 (2), p.757-767

Language

English

Formats

Publication information

Publisher

Berlin/Heidelberg: Springer Berlin Heidelberg

More information

Scope and Contents

Contents

The purpose of this study was to compare long-term neurocognitive functioning (working memory, processing speed, and attention) between children who had been treated with either propranolol or atenolol for infantile hemangioma during infancy. All eligible children (
n
 = 158) aged 6 years or older and treated with propranolol or atenolol as infants were invited to participate in this two-center cross-sectional study. The primary outcome was the Wechsler Intelligence Scale for Children-V Cognitive Proficiency Index (CPI), a measure of working memory, processing speed, and attention. Secondary outcomes were general intelligence, auditory, visuospatial, and narrative memory, as well as executive functioning and sleep. A total of 105 children, of whom 36 had been treated with propranolol (age 6.0–11.8 years, follow-up time 1.6–9.7 years, 19% male) and 69 had been treated with atenolol (age 6.9–9.7 years, follow-up time 4.5–8.4 years, 19% male), were analyzed. The CPI and other neurocognitive outcomes did not differ between the propranolol and atenolol groups and were in line with general population test norms. Post hoc analyses revealed lower CPI scores for males, both compared to participating females (10.3 IQ points, medium effect size) and compared to matched test norms (12.4 IQ points, medium effect size).
Conclusions
: Long-term neurocognitive functioning did not differ between children treated with propranolol and those treated with atenolol for IH. Overall, propranolol and atenolol appear to be safe treatments for IH regarding long-term neurocognitive functioning. The substantially lower CPI scores in males warrant further investigation.
Trial registration
: Netherlands Trial Register, NL7703
https://www.trialregister.nl/trial/7703
What is Known:
• 
Infants with infantile hemangioma are effectively treated with propranolol or atenolol.
• 
Parents and professionals are concerned about long-term neurocognitive effects.
What is New:
• 
No long-term (
≥ 
6 years) differences in neurocognitive functioning were found between children treated with...

Alternative Titles

Full title

Long-term neurocognitive functioning of children treated with propranolol or atenolol for infantile hemangioma

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9899165

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9899165

Other Identifiers

ISSN

1432-1076,0340-6199

E-ISSN

1432-1076

DOI

10.1007/s00431-022-04674-7

How to access this item